Positions

Overview

  • Dr. Luckhardt completed her medical training in May 2000 from the Louisiana State University Health Sciences Center in Shreveport, Louisiana, where she graduated Alpha Omega Alpha. She completed her Internal Medicine training at the University of Iowa Hospitals and Clinics in 2003. She was Chief Resident of Internal Medicine at the University of Iowa from 2003-2004. She then completed her Pulmonary and Critical Care Training at the University of Michigan. She was appointed as faculty there from 2007 until 2009 when she joined the faculty at UAB. Dr. Luckhardt has also completed a Masters program at the University of Michigan in 2009 in Clinical Research Design and Biostatistics. She has served on the American Thoracic Society Training committee, and on the University of Michigan's Pulmonary Fellow's Education committee.

    Dr. Luckhardt has particular interests in evaluating and treating patients with interstitial lung disease. She is working to build collaborations with Rheumatology and Cardiology to treat patients with interstitial lung disease and in particular patients with connective tissue disease-associated ILD. Dr. Luckhardt is also the Medical Director of the inpatient Pulmonary services and the Specialty Care Unit and has interest in the management of patients with advanced lung disease and chronic respiratory failure.
  • Selected Publications

    Chapter

    Year Title Altmetric
    2010 Addictive Disorders in the Intensive Care Unit.  167-179. 2010

    Research Overview

  • To complement her clinical interest in interstitial lung disease, Dr. Luckhardt has undertaken basic and translational investigations into the pathogenesis of idiopathic pulmonary fibrosis. She is principal investigator and co-investigator on multiple industry sponsored clinical trials in IPF and CTD-ILD. She also has a grant from the Pulmonary Fibrosis Foundation to study frailty as an outcome measure for IPF.
  • Principal Investigator On

  • Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis  awarded by Pulmonary Fibrosis Foundation
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry  awarded by Duke University
  • Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)  awarded by University of Pittsburgh The
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by PRIME EDUCATION LLC
  • Private Grant  awarded by GALAPAGOS NV.
  • Private Grant  awarded by FIBROGEN, INC.
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary FibrosiCleanUP-IPF  awarded by Weill (Joan and Sanford I.) Medical College of Cornell University
  • Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis – CleanUP-IPF  awarded by University of Pittsburgh The
  • TLR9 Activation and Fibrotic Responses in Alveolar Epithelial Cells  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • UAB Interstitial Lung Disease Program  awarded by Pulmonary Fibrosis Foundation
  • Investigator On

  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro)  awarded by Duke University
  • PAI-1 and Aging-Related Susceptibility to Lung Fibrosos  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by FIBROGEN, INC.
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by VERILOGUE, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by INTERMUNE, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC.
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by MALLINCKRODT ARD, INC
  • Private Grant  awarded by BIOGEN MA INC
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD
  • Private Grant  awarded by GENKYOTEX SA
  • Private Grant  awarded by RESPIVANT SCIENCES, GMBH
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by BELLEROPHON PULSE TECHNOLOGIES LLC
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PURE TECH HEALTH LLC
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan
  • Rituximab Therapy in Patients with IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Core C: Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS
  • Teaching Overview

  • Dr. Luckhardt has served as a mentor for several fellows pursuing translational and outcomes based projects in interstitial lung disease.
  • Education And Training

  • University of Iowa Hospitals and Clinics, Internship
  • University of Iowa Hospitals and Clinics, Residency
  • University of Michigan Hospitals & Health Centers, Postdoctoral Fellowship
  • Doctor of Medicine, Louisiana State University System : Shreveport 2000
  • Full Name

  • Tracy Luckhardt